Caroverine
| File:Caroverine.png | |
| Clinical data | |
|---|---|
| Trade names | Spasmium, Tinnitin, Tinnex |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22H27N3O2 |
| Molar mass | 365.477 g·mol−1 |
| 3D model (JSmol) | |
| |
| ☒check (what is this?) (verify) | |
Caroverine is an antispasmodic drug used in Austria and Switzerland to relieve spasms in smooth muscles, as well as to treat cerebrovascular diseases and tinnitus.[1]
Chemically, it is a quinoxalineone[2] and is available in both a base and hydrochloric acid forms.[1]
Pharmacology
[edit | edit source]Pharmacologically, it has been described as a nonspecific calcium channel blocker and as an antagonist of the NMDA receptor and other receptors.[3][4]
History
[edit | edit source]It was discovered in Austria in the 1950s[3] and was developed by Austrian company Phafag AG.[3]
Its international nonproprietary name (INN), caroverine, was proposed in 1972.[5]
Society and culture
[edit | edit source]Brand names
[edit | edit source]As of 2018, it was marketed under the brand names Spasmium and Tinnitin in Austria, and under the brand Tinnex in India.[6]
Research
[edit | edit source]An intravenous formulation was tested in a single-blinded study in tinnitus that published in 1997 and had positive results; an effort to replicate those results failed to show any effect,[4] and more people had their condition worsen than experienced benefit.[3] Pilot studies using a spray formulation for tinnitus published in 2005.[7]
In 2010 Phafag licensed rights to caroverine to the Indian company, Lincoln Pharmaceuticals, to develop the drug for tinnitus in India.[8] Lincoln first marketed it for that purpose in India in 2011.[9]
As of 2016 it had been studied in a small clinical trial in people with loss of the sense of smell.[10]
References
[edit | edit source]- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c d Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).